Abbott Looks to Sell Flu Vaccine Unit

Reuters reports that Abbott Laboratories is exploring the sale of its flu vaccine unit acquired as part of its purchase of Solvay''s drugs unit. Illinois-based Abbott earlier this year completed its $6.2 billion acquisition of Belgium''s Solvay Pharmaceuticals. The unit''s flu vaccine Influvac had 162 million euros ($197 million) in sales last year, with its sales occurring outside the United States.